Rules-Based Medicine Newswire (Page 6)

Rules-Based Medicine Newswire (Page 6)

Comprehensive Real-Time News Feed for Rules-Based Medicine. (Page 6)

Results 101 - 120 of 450 in Rules-Based Medicine

  1. The Myriad myPath Melanoma Test Effectively Diagnosed Patients in the ...Read the original story

    Oct 27, 2016 | Customer Interaction Solutions

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced it will present two new studies at the American Society of Dermatopathology annual meeting being held Oct. 27-30, 2016 in Chicago, Ill. The research being presented validates the accuracy of Myriad myPathA Melanoma in differentiating benign skin nevi from malignant melanoma.

    Comment?

  2. Myriad Genetics Inc. (MYGN) Short Interest Up 21.9% in OctoberRead the original story w/Photo

    Oct 27, 2016 | AmericanBankingNews.com

    Myriad Genetics Inc. saw a large growth in short interest in October. As of October 14th, there was short interest totalling 23,021,362 shares, a growth of 21.9% from the September 30th total of 18,889,611 shares.

    Comment?

  3. Exclusive: Myriad Genetics Discusses The Growing Market In Genetic TestingRead the original story w/Photo

    Oct 26, 2016 | Benzinga

    Myriad Genetics, Inc. is a molecular diagnostic company engaged in the development and marketing of transformative molecular diagnostic tests. The company recently announced a new relationship with ION Solutions, a part of AmerisourceBergen Corp. , to deliver hereditary cancer tests and services to its members.

    Comment?

  4. Myriad's BRACAnalysis CDx Test Identifies Patients with Ovarian...Read the original story

    Oct 26, 2016 | PressReleasePoint

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDxA test accurately identified patients who may benefit from treatment with olaparib. The BRACAnalysis CDx test was included in the SOLO2 study as a diagnostic with olaparib, an oral PARP inhibitor being developed by AstraZeneca .

    Comment?

  5. Myriad Genetics's BRACAnalysis CDx Test Identifies Patients With...Read the original story

    Oct 25, 2016 | BioSpace

    Myriad Genetics 's BRACAnalysis CDx Test Identifies Patients With Ovarian Cancer Who Would Benefit From Second-Line Maintenance Treatment With Olaparib SALT LAKE CITY, Utah, Oct. 26, 2016 - Myriad Genetics, Inc. , a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDxA test accurately identified patients who may benefit from treatment with olaparib. The BRACAnalysis CDx test was included in the SOLO2 study as a diagnostic with olaparib, an oral PARP inhibitor being developed by AstraZeneca .

    Comment?

  6. BB&T Corp Buys 4,853 Shares of Myriad Genetics Inc.Read the original story w/Photo

    Oct 25, 2016 | Daily Political

    BB&T Corp boosted its stake in Myriad Genetics Inc. by 3.8% during the second quarter, Holdings Channel reports. The fund owned 131,297 shares of the company's stock after buying an additional 4,853 shares during the period.

    Comment?

  7. Myriad Genetics Inc. (MYGN) Lowered to "Sell" at Zacks Investment ResearchRead the original story w/Photo

    Oct 25, 2016 | AmericanBankingNews.com

    According to Zacks, "Myriad ended fiscal 2016 with a disappointing fourth-quarter result. Revenue decline in hereditary cancer testing business remained the major deterrent in the fourth quarter.

    Comment?

  8. Myriad RBM Announces an Agreement with Sanofi to Measure Predictive...Read the original story

    Oct 25, 2016 | PressReleasePoint

    Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. , today announced that it will work with Sanofi, a global and diversified healthcare leader, to perform a biomarker analysis of blood samples from the Evaluation of Lixisenatide in Acute Coronary Syndrome trial . " said Riccardo Perfetti, head of Global Diabetes Medical Team, Sanofi.

    Comment?

  9. Myriad Genetics and ION Solutions partner to provide accurate, comprehensive hereditary cancer testsRead the original story w/Photo

    Oct 24, 2016 | Medical News

    Myriad Genetics, Inc. , a global leader in personalized medicine, and ION Solutions, a part of AmerisourceBergen, and the largest physician services organization specializing in the support of community oncology, announced today that they have entered into a relationship to deliver quality hereditary cancer test results and services to ION member practices. Through this relationship, Myriad and ION will work together to enhance the operational and clinical value associated with hereditary cancer testing.

    Comment?

  10. Myriad Genetics Inc. Forms Relationship with ION Solutions to Deliver ...Read the original story

    Oct 21, 2016 | PressReleasePoint

    Myriad Genetics, Inc. , a global leader in personalized medicine, and ION Solutions, a part of AmerisourceBergen, and the largest physician services organization specializing in the support of community oncology, announced today that they have entered into a relationship to deliver quality hereditary cancer test results and services to ION member practices. Through this relationship, Myriad and ION will work together to enhance the operational and clinical value associated with hereditary cancer testing.

    Comment?

  11. Myriad to Announce Fiscal First-Quarter 2017 Financial Results on November 1Read the original story

    Oct 20, 2016 | P&T Community

    Myriad Genetics, Inc. today announced that it will hold its fiscal first-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, November 1, 2016. During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, CFO, will provide an overview of Myriad's financial performance for the fiscal first-quarter and provide a business update.

    Comment?

  12. U.S. Clinical Oncology NGS Market Worth $1.53 Billion by 2024: Grand View Research,...Read the original story w/Photo

    Oct 19, 2016 | Freshnews

    U.S market for clinical oncology next generation sequencing ] is anticipated to reach USD 1.53 billion by 2024, according to a new report by Grand View Research, Inc. Application of NGS platform for clinical oncology are expected to grow at a steady pace under the influence of increasing adoption of NGS platforms in oncology R&D coupled with rising incidents of cancer. Application of NGS based cancer diagnostics for screening and monitoring of oncogenes to understand the underlying mechanism behind causes of cancer is expected to boost growth of this vertical throughout the forecast period.

    Comment?

  13. Myriad Genetics Teams Up With Project BioEYES To Advance STEM Education In UtahRead the original story

    Oct 17, 2016 | BioSpace

    Employees Will Facilitate Classroom Learning and Inspire Students to Pursue Careers in Science SALT LAKE CITY, Oct. 18, 2016 - Myriad Genetics, Inc. , a leader in molecular diagnostics and personalized medicine, announced today that more than 40 of its employees are volunteering to support Project BioEYES, which is a science, technology, engineering and math education program designed to teach K-12 students about cell biology, genetics and careers in science. Employees will spend a day in the classroom helping students formulate scientific hypotheses, design experiments and collect data, as well as sharing their own experiences from working in the life sciences.

    Comment?

  14. Myriad Genetics Will Present New Data On Its Variant Classification Program At The Annual MeetingRead the original story

    Oct 16, 2016 | BioSpace

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced it will present four new studies at the American Society of Human Genetics Annual Meeting being held Oct. 18-22, 2016 in Vancouver, British Columbia. The research being presented highlights the clinical utility of Myriad's myVisionA Variant Classification Program and myRisk Hereditary Cancer gene panel test.

    Comment?

  15. Myriad Will Present New Data on Its Variant Classification Program at the ASHG Annual MeetingRead the original story

    Oct 17, 2016 | Customer Interaction Solutions

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced it will present four new studies at the American Society of Human Genetics Annual Meeting being held Oct. 18-22, 2016 in Vancouver, British Columbia. The research being presented highlights the clinical utility of Myriad's myVisionA Variant Classification Program and myRisk Hereditary Cancer gene panel test.

    Comment?

  16. UBS Asset Management Americas Inc. Lowers Position in Myriad Genetics Inc.Read the original story w/Photo

    Oct 14, 2016 | Daily Political

    UBS Asset Management Americas Inc. reduced its stake in shares of Myriad Genetics Inc. by 53.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The firm owned 46,123 shares of the company's stock after selling 53,197 shares during the period.

    Comment?

  17. Myriad Genetics' (MYGN) "Sell" Rating Reiterated at Bank of America Corp.Read the original story w/Photo

    Oct 14, 2016 | Daily Political

    Several other research firms have also weighed in on MYGN. Mizuho dropped their price objective on shares of Myriad Genetics from $34.00 to $22.00 and set a neutral rating on the stock in a research note on Wednesday, August 10th.

    Comment?

  18. Tesaro Tops The Risers While Bristol-Myers Read the original story w/Photo

    Oct 13, 2016 | Seeking Alpha

    Esmo proved itself the must-attend cancer conference this year, with hugely important data in lung cancer stealing the show. The meeting also demonstrated its ability to move share prices, with clear winners and losers emerging.

    Comment?

  19. Myriad Genetics Inc. (MYGN) Downgraded by Ladenburg ThalmannRead the original story w/Photo

    Oct 13, 2016 | Daily Political

    Ladenburg Thalmann currently has $16.00 price target on the stock. A number of other research analysts also recently commented on the company.

    Comment?

  20. Myriad Genetics Inc. (MYGN) Sees Significant Increase in Short InterestRead the original story w/Photo

    Oct 13, 2016 | AmericanBankingNews.com

    Myriad Genetics Inc. was the target of a significant growth in short interest in September. As of September 30th, there was short interest totalling 18,889,611 shares, a growth of 13.7% from the September 15th total of 16,609,436 shares.

    Comment?